Quick facts about Optune
Optune is a noninvasive, portable device that is classified as durable medical equipment (DME).
Optune provides continuous action against disease progression by delivering Tumor Treating Fields (TTFields) to selectively disrupt mitosis in dividing cancer cells.
- Watch how TTFields can disrupt cancer cell division. This video shows the mechanism of action of TTFields
Transducer arrays are applied to the shaved scalp and must be changed at least 2 times per week (every 4 days, at most)
- Arrays should always have good scalp contact
- Note: Avoid activities that may result in the device or transducer arrays becoming wet. Getting the device wet may cause it damage
Recommended usage goal for Optune is 18+ hrs/day, which gives patients flexibility to decide which times of day are best for use4
Patients can benefit most from wearing Optune for the recommended time
In the phase 3 pivotal trial, 75% of patients used Optune 18 or more hours a day during the first 3 months of treatment5
- 50% daily use was the threshold for significant survival benefit over TMZ alone
- 86% of patients received a survival benefit from Optune, because they used it more than half the time (n=388/450)
Adjusting to Optune
- This brief video shows Optune users and caregivers providing their perspectives on starting to use Optune
Simple steps to start patients on Optune
Novocure® has identified a 4-step process that may help your patients with GBM start Optune and achieve their treatment goals.
GBM, glioblastoma; TMZ, temozolomide.
References: 1. Optune. Instructions for Use for Glioblastoma. Novocure; 2019. 2. China NMPA approves Optune® for the treatment of newly diagnosed and recurrent glioblastoma [press release]. St. Helier, Jersey and Shanghai: Business Wire; May 13, 2020. Accessed December 7, 2020. 3. Novocure Data on File OPT-115.3. 4. Optune. Patient Information and Operation Manual. Novocure; 2019. 5. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316.